Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

In the past decades, when dacarbazine-based chemotherapy was the treatment of choice, the median survival of patients with unresectable melanoma was only six to nine months and only 10–15% of the p...